These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26666379)

  • 21. [Antiviral therapy of hepatitis C].
    Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
    Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virus-positive donors.
    Berenguer M
    Liver Transpl; 2016 Nov; 22(S1):47-51. PubMed ID: 27465590
    [No Abstract]   [Full Text] [Related]  

  • 23. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus resistance to the new direct-acting antivirals.
    Esposito I; Trinks J; Soriano V
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
    Pár A
    Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current management of hepatitis C].
    Lange CM
    Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral determinants of resistance to treatment in patients with hepatitis C.
    Wohnsland A; Hofmann WP; Sarrazin C
    Clin Microbiol Rev; 2007 Jan; 20(1):23-38. PubMed ID: 17223621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
    Chowdhury R; Tsen A
    Am J Kidney Dis; 2017 Aug; 70(2):301-304. PubMed ID: 28343737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New pharmacotherapy for hepatitis C.
    Assis DN; Lim JK
    Clin Pharmacol Ther; 2012 Sep; 92(3):294-305. PubMed ID: 22850602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in and the future of treatments for hepatitis C.
    Cheng R; Tu T; Shackel N; McCaughan GW
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):633-47. PubMed ID: 24846594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study: longer duration of posttransplant hepatitis C virus therapy may increase the sustained response rate.
    Karasu Z; Akay S; Yilmaz F; Akarca U; Ersoz G; Gunsar F; Kilic M
    Transplant Proc; 2009 Nov; 41(9):3806-9. PubMed ID: 19917392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
    Welsch C
    Drug Discov Today Technol; 2014 Mar; 11():19-25. PubMed ID: 24847649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.
    Zoulim F; Locarnini S
    Liver Int; 2013 Feb; 33 Suppl 1():116-24. PubMed ID: 23286855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of chronic hepatitis C.
    Bihl F; Negro F
    Minerva Med; 2009 Dec; 100(6):459-65. PubMed ID: 20010481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The therapy of hepatitis C in the failure of interferon].
    Hermann R; Maier KP
    Dtsch Med Wochenschr; 1997 Aug; 122(34-35):1049-54. PubMed ID: 9312461
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety of direct antiviral agents in the management of hepatitis C.
    El Kassas M; Elbaz T; Hafez E; Esmat G
    Expert Opin Drug Saf; 2016 Dec; 15(12):1643-1652. PubMed ID: 27661100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.